News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

New drug will combat NZ's high Hepatitis B rate

PHARMAC says its decision to subsidise a new drug for Hepatitis B will complement a screening programme for the disease.

The Government’s drug funding agency says treatment with the drug lamivudine will mean fewer people with Hepatitis B will die prematurely, and more will experience a better quality of life.

PHARMAC’s General Manager Wayne McNee says subsidising lamivudine ties in with the Government-funded Hepatitis B screening programme, which identifies non-carriers of the virus for vaccination.

“With lamivudine, now there is an effective treatment for people who are found to have chronic active infection. This is great news as Hepatitis B is an extremely serious public health issue for New Zealanders, ” he says.

The number of Hepatitis B carriers in New Zealand is high by international standards, with an estimated 55,000 carriers of the virus, and another 16,000 with active chronic infection.

Wayne McNee says it is estimated that up to a quarter of those with active chronic infection will die a premature death from cirrhosis of the liver or liver cancer.

But he says lamivudine (brand name Zeffix) has been shown to be more successful in eliminating the virus than the current treatment with interferon alpha. And he says it will reduce the numbers of people progressing to advanced disease. Lamivudine also has fewer side effects.

“Many people don’t realise how serious Hepatitis B is. Anything to reduce the number of premature deaths and give a better quality of life to those people who are infected is a good thing,” he says.

Wayne McNee says the new drug is particularly good news for Maori, Pacific Island, and Asian peoples.

“The Hepatitis B virus is particularly prevalent in those three groups – about five percent of them carry the virus compared to one percent in other groups. It is estimated that about one in three of those who carry the virus will develop chronic active infection,” he says.

PHARMAC expects to spend about $5 million on the drug but says that will tail off because children are now immunised against Hepatitis B, so as they get older there will be fewer cases to treat.

[ends]

For more information contact General Manager Wayne McNee. Phone: (025) 429-212.


© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis Review: Tarantino's Pitch-Perfect Once Upon a Time … in Hollywood

Welcome back to the violent and misogynistic, yet always entertaining world of Quentin Tarantino, who this time around focuses his dyspeptic lens on Tinseltown's pimply backside. More>>


Westpac Exiting Cake Tin: Stadium Announces Naming Rights Agreement With Sky

Wellington Regional Stadium Trust (WRST) and Sky Network Television Ltd (Sky) have announced a new partnership that will see Sky secure the naming rights of the Stadium from 1 January 2020. More>>

ALSO:

ASB Classic: Serena Williams Confirmed For 2020

One of the biggest names in sport has confirmed she will be returning to the ASB Classic in 2020. Twenty-three time Grand Slam singles champion Serena Williams will return to Auckland’s ASB Tennis Arena to challenge for the ASB Classic title. More>>


Netball: Taurua To Coach Silver Ferns Through Two More Campaigns

Netball New Zealand has confirmed Taurua will guide the Silver Ferns as they take on the Australian Diamonds in October’s Cadbury Netball Series (Constellation Cup), along with the Northern Quad Series in late January. More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland